Various immunological strategies in the treatment of pancreatic cancer have been pursued, including stimulation of the patient’s native immune system to fight off the malignancy with cytokines as granulocyteCmacrophage colony-stimulating factor (GM-CSF) [23], interleukin (IL)-6 [24] and immune response modifiers such as Virulizin [25]. (IgG, IgM, IgA). Flow cytometry and immunofluorescence microscopy exhibited comparable presence of IgG and IgE pancreatic cancer Igs. However, Western blot analysis indicated differences in IgG and IgE antigen-specific antibodies; IgE antibody recognized a 50 kD protein. ADCC studies exhibited that serum and purified IgE-mediated cytotoxicity against pancreatic cancer cells, effects which were GHRP-6 Acetate reversed with anti-IgE neutralizing antibody and IgE depletion (immunoaffinity); greater cytotoxicity was observed in patient serum when compared with healthy controls. These data suggest that IgE and sCD23 may serve as useful biomarkers for patients with pancreatic cancer and may be important in the immune response to this disease in that IgE-directed GHRP-6 Acetate therapy may help to direct treatment. Keywords: ADCC, adenocarcinoma, CD23, cytotoxicity, IgE, IgE receptor, immunoglobulins, GHRP-6 Acetate pancreatic cancer Introduction Pancreatic cancer continues to be one of the leading causes of cancer-related death in the United States [1] despite surgical treatment and numerous recent therapeutic interventions, such as gemcitabine [2] and topoisomerase inhibitors [3]. As predisposing host factors remain unclear [4], early diagnosis of this disease is extremely difficult, with the diagnosis usually made through imaging techniques with subsequent histopathological confirmation from biopsy specimens. In most cases, patients present in late stages of the disease and are thus no longer amenable to surgery. Therefore, it is imperative to find better diagnostic evaluations of this disease in addition to better therapeutic interventions in order to make an impact around the lethal sentence associated with the diagnosis of this disease. The aetiology and biology of pancreatic cancer is probably multi-factorial [5]. Viral contamination has been postulated as a precedence or contributor to pancreatic cancer pathogenesis [6C11]. Others have suggested recently that allergic status correlated with cancer prognosis and survival; that patients with allergic diseases had a decreased risk for pancreatic and other cancers [12C15]. In this regard we have exhibited previously that immunoglobulin (Ig)E anti-viral Mouse monoclonal to p53 antibodies obtained from nonallergic patients may provide a beneficial role in human immunodeficiency virus (HIV) and other viral diseases [16C18]; the presence and persistence of IgE anti-viral antibodies may contribute to IgE immunosurveillance and effect pathogenesis. In those studies we have shown that IgE can directly inhibit viral production and destroy virus-infected cells, probably by antibody-dependent cell-mediated cytotoxicity (ADCC) [16]. With regard to the role of IgE in malignancy, recent studies by Karagiannis have investigated the role of IgE anti-cancer antibodies in ovarian carcinoma [19,20]. In those studies IgE antibodies were able to destroy ovarian cancer cells by ADCC. In addition, tumour-bearing nude mice showed prolonged survival with administration of anti-tumour IgE [19]. Recent studies by Wrensch and colleagues have reported that glioblastoma patients with elevated IgE had 9 months longer survival than those with normal or borderline IgE levels [21]. Here we investigated the role of IgE in pancreatic cancer and show that IgE is usually regulated uniquely with respect to other Ig isotypes and can destroy pancreatic cancer cells through ADCC mechanisms. These results provide a novel utility for IgE with respect to potential anti-cancer immunotherapy. Materials and methods Patient specimens Peripheral blood (5 ml total) was obtained from 12 pancreatic cancer patients treated at State University of New York Downstate and Kings County (KCH), Medical Center’s GI and Surgery Clinics and its GHRP-6 Acetate affiliates. Serum obtained from 15 healthy volunteers served as controls. Patients and controls did not have any history of recent contamination, atopy or parasitic infections. Patient consent for specimens and internal review board approval was obtained. Blood was collected into red-top monoject tubes (Sherwood Medical, St Louis, MO, USA) and allowed to clot for 30 min, after which tubes were spun at 800 and serum collected. Sera were stored at ?80C until analysis. Serum Igs (IgG, IgM, IgA, IgE) and soluble CD23 Serum Ig (IgG, IgM, IgA) levels were detected by nephelometry (MININEPH?, The Binding Site, San Diego, CA, USA) according to the manufacturer’s instructions. Total serum IgE and soluble CD23 (sCD23) levels were detected by enzyme-linked immunosorbent assay (ELISA) (IgE-BioQuant, San Diego, CA, USA; sCD23-BioSource, Camarillo, CA, USA) which was performed according to standard procedure. IgG, IgM and IgA are.